Compare YETI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YETI | KNSA |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2016 | 2018 |
| Metric | YETI | KNSA |
|---|---|---|
| Price | $38.94 | $45.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $46.54 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 1.4M | 595.3K |
| Earning Date | 05-21-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 2.03 | 0.75 |
| Revenue | ★ $1,868,494,000.00 | $677,564,000.00 |
| Revenue This Year | $9.13 | $38.01 |
| Revenue Next Year | $7.16 | $17.42 |
| P/E Ratio | ★ $19.90 | $61.29 |
| Revenue Growth | 2.11 | ★ 60.09 |
| 52 Week Low | $26.61 | $18.26 |
| 52 Week High | $51.29 | $49.12 |
| Indicator | YETI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 26.55 | 55.09 |
| Support Level | $30.87 | $40.47 |
| Resistance Level | $50.74 | $49.12 |
| Average True Range (ATR) | 1.90 | 2.11 |
| MACD | -0.71 | -0.01 |
| Stochastic Oscillator | 3.97 | 61.00 |
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.